Anti-Obesity Drugs Market Introduction and Overview
According to SPER Market Research, ‘Global Anti-Obesity Drugs Market Size – By Type, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Anti-Obesity Drugs Market is predicted to reach 79.26 billion by 2034 with a CAGR of 27.24%
Anti-obesity drugs are pharmaceutical treatments developed to combat excessive weight gain and the associated health complications, such as diabetes, hypertension, cardiovascular diseases, and certain cancers. These drugs work through various mechanisms, including appetite suppression, enhanced fat metabolism, and reduced calorie absorption, offering a solution for individuals who struggle to lose weight through diet and exercise alone.
Restraints: The market for anti-obesity medications has a number of obstacles in spite of its promise. Accessibility is restricted by the high expense of pharmaceuticals, particularly in low- and middle-income nations. Patients and healthcare professionals are discouraged from widespread adoption by safety concerns, which include side effects including cardiovascular risks or gastrointestinal problems. Critical obstacles include limited long-term efficacy and the considerable risk of weight return following therapy discontinuation.
Scope of the Report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Type, By Distribution Channel.
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.
Companies Covered
Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novo Nordisk A/S, Pfizer Inc, Sandoz International GmbH, VIVUS LLC. and others.
Anti-Obesity Drugs Market Segmentation:
By Type: Based on the Type, Global Anti-Obesity Drugs Market is segmented as; Prescription Drugs and OTC Drugs.
By Distribution Channel: Based on the Distribution Channel, Global Anti-Obesity Drugs Market is segmented as; Hospital Pharmacy and Online & Retail Pharmacy.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Anti-Obesity Drugs Market Manufacturing Base Distribution, Sales Area, Interface Type
- 6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Anti-Obesity Drugs Market
- 7. Global Anti-Obesity Drugs Market, By Type (USD Million) 2021-2034
- 7.1. Prescription Drugs
- 7.2. OTC Drugs
- 8. Global Anti-Obesity Drugs Market, By Distribution Channel (USD Million) 2021-2034
- 8.1. Hospital Pharmacy
- 8.2. Retail and Online Pharmacy
- 9. Global Anti-Obesity Drugs Market, (USD Million) 2021-2034
- 9.1. Global Anti-Obesity Drugs Market Size and Market Share
- 10. Global Anti-Obesity Drugs Market, By Region, (USD Million) 2021-2034
- 10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
- 10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
- 10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
- 10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
- 10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America
- 11. Company Profile
- 11.1. Boehringer Ingelheim International GmbH
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Interface summary
- 11.1.4. Recent developments
- 11.2. Currax Pharmaceuticals LLC
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Interface summary
- 11.2.4. Recent developments
- 11.3. F. Hoffmann-La Roche Ltd
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Interface summary
- 11.3.4. Recent developments
- 11.4. GlaxoSmithKline plc
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Interface summary
- 11.4.4. Recent developments
- 11.5. Novo Nordisk A/S
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Interface summary
- 11.5.4. Recent developments
- 11.6. Pfizer Inc
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Interface summary
- 11.6.4. Recent developments
- 11.7. Sandoz International GmbH
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Interface summary
- 11.7.4. Recent developments
- 11.8. VIVUS LLC
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Interface summary
- 11.8.4. Recent developments
- 11.9. Others
- 12. Conclusion
- 13. List of Abbreviations
- 14. Reference Links
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook